Patients’ characteristics at baseline (MFAS)
| Azithromycin (N=102) | Tobramycin (N=101) | |
|---|---|---|
| Gender, n (%) | ||
| Male | 51 (50.0) | 51 (50.5) |
| Age (years), mean±SD | 2.7±3.0 | 3.2±3.9 |
| Age category, n (%) | ||
| <24 months | 57 (55.9) | 55 (54.5) |
| 24 months to <4 years | 15 (14.7) | 16 (15.8) |
| 4 years to <12 years | 29 (28.4) | 24 (23.8) |
| 12 years to ≤18 years | 1 (1.0) | 6 (5.9) |
| Bulbar conjunctival injection*, n (%) (worse eye) | ||
| Absent | 4 (3.9) | 4 (4.0) |
| Mild | 33 (32.4) | 28 (27.7) |
| Moderate | 55 (53.9) | 58 (57.4) |
| Severe | 10 (9.8) | 11 (10.9) |
| Conjunctival purulent discharge*, n (%) (worse eye) | ||
| Absent | 0 (0.0) | 0 (0.0) |
| Mild | 16 (15.7) | 10 (9.9) |
| Moderate | 54 (52.9) | 62 (61.4) |
| Severe | 32 (31.4) | 29 (28.7) |
*Between-group difference not significantly different (p=0.559 for bulbal conjunctival injection and p=0.729 for conjunctival purulent discharge; CMH test, stratified by age group).
CMH, Cochran–Mantel–Haenszel; MFAS, microbiologically positive full analysis set.